Triple

T15921467
Position Surface form Disambiguated ID Type / Status
Subject CEP E386102 entity
Predicate fullForm P2351 FINISHED
Object Certificate of Suitability to the monographs of the European Pharmacopoeia E386103 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Certificate of Suitability to the monographs of the European Pharmacopoeia | Statement: [CEP, fullForm, Certificate of Suitability to the monographs of the European Pharmacopoeia]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Certificate of Suitability to the monographs of the European Pharmacopoeia
Context triple: [CEP, fullForm, Certificate of Suitability to the monographs of the European Pharmacopoeia]
  • A. Certificates of Suitability to the monographs of the European Pharmacopoeia chosen
    Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
  • B. European Pharmacopoeia
    The European Pharmacopoeia is a legally binding reference work that sets quality standards for medicines and their ingredients across member states of the Council of Europe.
  • C. ICH Q1 Stability Testing of New Drug Substances and Products
    ICH Q1 Stability Testing of New Drug Substances and Products is an international regulatory guideline that defines the scientific principles and study requirements for assessing the stability, shelf life, and storage conditions of new pharmaceutical substances and finished products.
  • D. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
    The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
  • E. ICH Q11 Development and Manufacture of Drug Substances
    ICH Q11 Development and Manufacture of Drug Substances is an ICH guideline that provides principles and expectations for the development and manufacturing of chemical and biotechnological drug substances within a quality-by-design framework.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d86da686e4819097cbf3b1fc2d881d completed April 10, 2026, 3:25 a.m.
NER Named-entity recognition batch_69e156818cbc819086c956475ad23825 completed April 16, 2026, 9:37 p.m.
NED1 Entity disambiguation (via context triple) batch_69ffb5a96e508190a64c2be6dc506e86 completed May 9, 2026, 10:31 p.m.
Created at: April 10, 2026, 4:52 a.m.